Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus TACE versus TACE alone for recurrent hepatocellular carcinoma
ChiCTR-IPR-17012667Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Sep 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: Progression-free survival. Started Sep 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-IPR-17012667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012667.